Oncocross Corrects Quarterly Report, Adds Disclosure of Financial Supervisory Service Fine of 87.3 Million Won; No Financial Impact

Oncocross corrected its quarterly report for the first quarter of 2026 on July 20, 2026, adding disclosure of a total fine of 87.3 million won imposed by the Financial Supervisory Service.
The fines resulted from violations of securities registration requirements during the issuance of redeemable convertible preferred shares in 2020 and common shares in 2021. The company has already paid the fines and strengthened internal procedures.
This amendment only adds footnote disclosures without changing any financial figures, so no additional financial shock is expected. However, the revealed past non-compliance may negatively affect investor sentiment in the short term.
[AI Summary]Oncocross added disclosures of FSS fines through a correction to its quarterly report. The fines were already paid, so the financial impact is negligible, but the history of securities registration omissions during the pre-listing period may undermine trust in internal controls and weigh on the stock price.